Cargando…
The Role of Proteasome Inhibition in Nonsmall Cell Lung Cancer
Lung cancer therapy with current available chemotherapeutic agents is mainly palliative. For these and other reasons there is now a great interest to find targeted therapies that can be effective not only palliating lung cancer or decreasing treatment-related toxicity, but also giving hope to cure t...
Autores principales: | Escobar, Mauricio, Velez, Michel, Belalcazar, Astrid, Santos, Edgardo S., Raez, Luis E. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3100637/ https://www.ncbi.nlm.nih.gov/pubmed/21629760 http://dx.doi.org/10.1155/2011/806506 |
Ejemplares similares
-
Emerging role of multikinase inhibitors for refractory thyroid cancer
por: Perez, Cesar A, et al.
Publicado: (2012) -
Proteasome inhibitors in the treatment of nonsmall cell lung cancer: A systematic review of clinical evidence
por: Chua, Alethea Dasha Wenning, et al.
Publicado: (2023) -
Personalised medicine for nonsmall cell lung cancer
por: Mascaux, Céline, et al.
Publicado: (2017) -
Modern therapies of nonsmall cell lung cancer
por: Jachowski, Andrzej, et al.
Publicado: (2023) -
Efficacy of sorafenib, a multi-tyrosine kinase inhibitor, in an adenoid cystic carcinoma metastatic to the lung: case report and review of literature
por: Dammrich, Daniel J, et al.
Publicado: (2011)